EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Oral Mucositis - Pipeline Review, H1 2017

  • ID: 4143201
  • Report
  • March 2017
  • 91 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Cellceutix Corp
  • Clevexel Pharma SA
  • Galera Therapeutics Inc
  • Humanetics Corp
  • Onxeo SA
  • Oragenics Inc
  • MORE
Oral Mucositis - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides an overview of the Oral Mucositis (Oncology) pipeline landscape.

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Oral Mucositis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 2 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Oral Mucositis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Oncology).
- The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oral Mucositis (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oral Mucositis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Cellceutix Corp
  • Clevexel Pharma SA
  • Galera Therapeutics Inc
  • Humanetics Corp
  • Onxeo SA
  • Oragenics Inc
  • MORE
Introduction

Oral Mucositis - Overview

Oral Mucositis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Oral Mucositis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Oral Mucositis - Companies Involved in Therapeutics Development

Cellceutix Corp

Clevexel Pharma SA

Colby Pharmaceutical Company

Galera Therapeutics Inc

Humanetics Corp

Onxeo SA

Oragenics Inc

Otsuka Holdings Co Ltd

Soligenix Inc

Spectrum Pharmaceuticals Inc

Spherium Biomed SL

Oral Mucositis - Drug Profiles

AG-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCD-600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brilacidin tetrahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

clonidine hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0095 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dusquetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-4419 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Oral Mucositis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate SOD2 for Oral Mucositis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HYLP-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-219 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pralatrexate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rebamipide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oral Mucositis - Dormant Projects

Oral Mucositis - Discontinued Products

Oral Mucositis - Product Development Milestones

Featured News & Press Releases

Jan 05, 2017: Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Dec 12, 2016: Soligenix Announces SGX942 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

Dec 08, 2016: Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis

Dec 08, 2016: Soligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Nov 21, 2016: U.S. FDA Grants Fast Track Designation for the Development of Oragenics AG013 for Oral Mucositis

Oct 26, 2016: Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications

Oct 18, 2016: Soligenix Announces Publication of its Phase 2 Clinical Trial Results of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Sep 27, 2016: Galera Therapeutics Announces Presentation of One-Year Follow-up Data from a Phase 1b/2a Study of GC4419 In the Reduction of Severe Oral Mucositis

Sep 06, 2016: Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs

Aug 30, 2016: Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment

Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis

Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference

Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis

May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol

Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Oral Mucositis, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Oral Mucositis - Pipeline by Cellceutix Corp, H1

Oral Mucositis - Pipeline by Clevexel Pharma SA, H1

Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H1

Oral Mucositis - Pipeline by Galera Therapeutics Inc, H1

Oral Mucositis - Pipeline by Humanetics Corp, H1

Oral Mucositis - Pipeline by Onxeo SA, H1

Oral Mucositis - Pipeline by Oragenics Inc, H1

Oral Mucositis - Pipeline by Otsuka Holdings Co Ltd, H1

Oral Mucositis - Pipeline by Soligenix Inc, H1

Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, H1

Oral Mucositis - Pipeline by Spherium Biomed SL, H1

Oral Mucositis - Dormant Projects, H1

Oral Mucositis - Dormant Projects, H1 2017 (Contd..1), H1

Oral Mucositis - Discontinued Products, H1

List of Figures:

Number of Products under Development for Oral Mucositis, H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Cellceutix Corp
  • Clevexel Pharma SA
  • Colby Pharmaceutical Company
  • Galera Therapeutics Inc
  • Humanetics Corp
  • Onxeo SA
  • Oragenics Inc
  • Otsuka Holdings Co Ltd
  • Soligenix Inc
  • Spectrum Pharmaceuticals Inc
  • Spherium Biomed SL
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll